VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

Ankara (MVA) Vaccine

Vaccine Information

Vaccine Name: Ankara (MVA) Vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007254
Type: Recombinant plasmid DNA
Status: Research
Antigen: Tyrosine, MART-1, NY-ESO-1
Immunization Route: Intramuscular injection (i.m.)
Description: A modified vaccinia Ankara (MVA) encoding 7 melanoma tumor antigen cytotoxic T lymphocyte (CTL) epitopes. (Smith et al., 2005)

Host Response

Human Response

Vaccine Immune Response Type: VO_0003057
Immune Response: CTL responses were generated to only 1 of the recombinant epitopes and the magnitude of these responses (0.029-0.19% CD8(+) T cells) was below the levels usually seen in acute viral infections (Smith et al., 2005).
Description: This vaccine was used in clinical trials involving melanoma.(Meyer et al., 2005)

References

Meyer et al., 2005: Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, Weigle B, Schmitz M, Mateo L, Schmidt B, Bernhard H, Jakob T, Hein R, Schuler G, Schuler-Thurner B, Wagner SN, Drexler I, Sutter G, Arndtz N, Chaplin P, Metz J, Enk A, Huber C, WÃ¶lfel T. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer immunology, immunotherapy : CII. 2005; 54(5); 453-467. [PubMed: 15627214].

Smith et al., 2005: Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC, Coulie P, Schneider J, Hoffman E, Hawkins R, Harris AL, Cerundolo V. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. International journal of cancer. Journal international du cancer. 2005; 113(2); 259-266. [PubMed: 15386406].